Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 45,680,260
  • Shares Outstanding, K 257,035
  • Annual Sales, $ 3,048 M
  • Annual Income, $ 2,097 M
  • 60-Month Beta 1.43
  • Price/Sales 14.85
  • Price/Cash Flow 55.82
  • Price/Book 8.93

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate 0.87
  • Number of Estimates 7
  • High Estimate 1.00
  • Low Estimate 0.62
  • Prior Year 0.76
  • Growth Rate Est. (year over year) +14.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
165.23 +7.56%
on 10/02/19
180.05 -1.29%
on 10/17/19
+1.72 (+0.98%)
since 09/17/19
3-Month
165.23 +7.56%
on 10/02/19
188.44 -5.69%
on 08/20/19
+0.58 (+0.33%)
since 07/17/19
52-Week
151.80 +17.08%
on 12/24/18
195.81 -9.24%
on 01/22/19
-7.76 (-4.18%)
since 10/17/18

Most Recent Stories

More News
Vertex Pharm Rises 3.30% on Heavy Volume: Watch For Potential Pullback

Vertex Pharm (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $177.50 to a high of $179.58. Yesterday, the shares gained 3.3%, which took the trading range above the 3-day high of...

VRTX : 177.72 (+0.93%)
Look for Shares of Vertex Pharm to Potentially Pullback after Yesterday's 3.30% Rise

Vertex Pharm (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $177.50 to a high of $179.58. Yesterday, the shares gained 3.3%, which took the trading range above the 3-day high of...

VRTX : 177.72 (+0.93%)
Will New Alliances Aid Quest Diagnostics (DGX) Q3 Earnings?

Quest Diagnostics (DGX) is likely to have retained its two-pronged agenda to accelerate growth and drive operational excellence in the third quarter.

VRTX : 177.72 (+0.93%)
DGX : 104.73 (-1.03%)
XRAY : 54.95 (+1.93%)
AKCA : 18.93 (-3.27%)
The Zacks Analyst Blog Highlights: Southern Company, Applied Materials, Vertex Pharmaceuticals, NVIDIA and Edwards Lifesciences

The Zacks Analyst Blog Highlights: Southern Company, Applied Materials, Vertex Pharmaceuticals, NVIDIA and Edwards Lifesciences

SO : 61.06 (-0.05%)
VRTX : 177.72 (+0.93%)
NVDA : 194.29 (+0.04%)
AMAT : 52.14 (+1.12%)
What's in Store for Edwards Lifesciences' (EW) Q3 Earnings?

The recent full-market launch of the HemoSphere platform with the FloTrac System and Acumen Hypotension Predictive Index should reflect in Edwards Lifesciences' (EW) third-quarter results.

EW : 227.80 (+0.65%)
VRTX : 177.72 (+0.93%)
XRAY : 54.95 (+1.93%)
AKCA : 18.93 (-3.27%)
Top Research Reports for Southern, Applied Materials & Vertex

Top Research Reports for Southern, Applied Materials & Vertex

VRTX : 177.72 (+0.93%)
SO : 61.06 (-0.05%)
NVDA : 194.29 (+0.04%)
EW : 227.80 (+0.65%)
BHP : 47.67 (-1.04%)
AMAT : 52.14 (+1.12%)
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?

Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VRTX : 177.72 (+0.93%)
Can Structural Heart Strength Aid Abbott (ABT) Q3 Earnings?

Abbott (ABT) has been growing popular with developments in its flagship, market leading device for the treatment of mitral regurgitation, MitraClip.

ABT : 82.38 (+0.73%)
VRTX : 177.72 (+0.93%)
XRAY : 54.95 (+1.93%)
AKCA : 18.93 (-3.27%)
Can Balanced Segmental Growth Aid Abbott (ABT) Q3 Earnings?

Abbott (ABT) is steadily gaining prominence for developments in its flagship, sensor-based continuous glucose monitoring (CGM) system of FreeStyle Libre.

ABT : 82.38 (+0.73%)
VRTX : 177.72 (+0.93%)
XRAY : 54.95 (+1.93%)
AKCA : 18.93 (-3.27%)
Can Vertex (VRTX) Keep the Earnings Surprise Streak Alive?

Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

VRTX : 177.72 (+0.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade VRTX with:

Business Summary

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs...

See More

Key Turning Points

2nd Resistance Point 180.97
1st Resistance Point 179.35
Last Price 177.72
1st Support Level 176.80
2nd Support Level 175.87

See More

52-Week High 195.81
Fibonacci 61.8% 179.00
Last Price 177.72
Fibonacci 50% 173.80
Fibonacci 38.2% 168.61
52-Week Low 151.80

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar